News | November 28, 2025
Piramal Pharma Solutions achieves global nitrosamine compliance, strengthening patient safety
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Observations are largely around improvement of procedures and practices
Subscribe To Our Newsletter & Stay Updated
